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CObjective: The Saphenous Vein Versus Right Internal Thoracic Artery as a Y-Composite Graft trial was de-
signed to evaluate the saphenous vein compared with the right internal thoracic artery as a Y-composite graft
anastomosed to the side of the left internal thoracic artery. In this early analysis, we compared early angiographic
patency rates and clinical outcomes.
Methods: From September 2008 to October 2011, 224 patients with multivessel coronary artery disease were
randomized prospectively to undergo off-pump revascularization using the saphenous vein group (n ¼ 112) or
the right internal thoracic artery group (n ¼ 112) as Y-composite grafts. Early postoperative (1.4  1.1 days)
angiographic patency and clinical outcomes were compared.
Results: There was 1 operative death in the right internal thoracic artery group. No statistically significant dif-
ferences in postoperative morbidities, including atrial fibrillation and acute renal failure, were observed between
the groups. The number of distal anastomoses using the side-arm Y-composite graft (saphenous vein vs right
internal thoracic artery) were 2.3  0.8 and 1.9  0.7 in the saphenous vein and right internal thoracic artery
groups, respectively (P<.001). A third conduit was used in 44 patients (saphenous vein group vs right internal
thoracic artery group, 4/109 vs 40/110; P<.001) to extend the side-arm Y-composite graft for complete revas-
cularization. Early angiography demonstrated an overall patency rate of 99.4% (771 of 776 distal anastomoses).
Patency rates of the side-arm Y-composite graft (saphenous vein vs right internal thoracic artery) were 98.8%
(245 of 248) and 99.5% (207 of 208) in the saphenous vein and right internal thoracic artery groups, respectively
(P ¼ .629).
Conclusions: A third conduit was needed to extend the right internal thoracic artery composite graft and reach
the target vessels in 36.4% (40/110) of the patients. The saphenous vein composite graft was comparable with
the right internal thoracic artery composite graft in terms of early angiographic patency and clinical outcomes. (J
Thorac Cardiovasc Surg 2012;144:1027-35)The saphenous vein (SV) has been one of the most widely
used conduits for coronary artery bypass grafting (CABG)
because of its advantages, such as easy accessibility, suffi-
cient length, short harvest time, and ease of manipulation.
However, there have been concerns about the suitability
of the SV graft in CABG resulting from structural and func-
tional differences between veins and arteries.1 Poor long-
term patency rates and clinical outcomes have been
reported after CABG performed with SV aortocoronary
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The Journal of Thoracic and Cargrafts.2-4 Of the various arterial grafts used in myocardial
revascularization, the right internal thoracic artery (ITA)
has been considered a second conduit of choice after
the left ITA.5,6 In our previous studies, we demonstrated
the merits of right ITA composite grafts in terms of
angiographic patency and clinical results.7-9
In another previous study by our group, the SV composite
graft showed a similar patency rate compared with the arte-
rial composite graft 1 year after surgery.10 The theoretical
advantages of using the SV as a composite graft based on
the in situ left ITA include less exposure to direct pressure
and circulatory stress from the ascending aorta and
continuous exposure to nitric oxide released from the in
situ left ITA.11,12 However, few studies using the SV as
a composite graft have been conducted.10,13,14 The
Saphenous Vein Versus Right Internal Thoracic Artery as
a Y-Composite Graft (SAVE RITA) trial is a randomized,
controlled clinical trial designed to evaluate the SV
compared with the right ITA as a Y-composite graft based
on the in situ left ITA in terms of 1-year angiographic pa-
tency rates and mid-term clinical outcomes. As an early
analysis, we compared early angiographic patency ratesdiovascular Surgery c Volume 144, Number 5 1027
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
ITA ¼ internal thoracic artery
OPCAB ¼ off-pump coronary artery bypass
grafting
RITA ¼ right internal thoracic artery
Y-composite graft
SAVE RITA ¼ Saphenous Vein Versus Right
Internal Thoracic Artery as
a Y-Composite Graft trial
SV ¼ saphenous vein
SVG ¼ saphenous vein Y-composite graft
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Dand clinical outcomes of CABG using the SVas a Y-compo-
site graft with those of CABG using the right ITA as
a composite graft.MATERIALS AND METHODS
The study protocol was approved by the institutional review board
(approval no. H-0803-024-237), and informed consent was obtained
from all study patients.
Study Design
The study was designed according to the Consolidated Standards of
Reporting Trials statement.15 Patients, 40 to 75 years of age, who were
scheduled to undergo off-pump CABG (OPCAB) for multivessel coronary
artery disease on a nonemergency basis and who were expected to receive
a Y-composite graft based on the in situ left ITAwere eligible for the study
if they had an estimated left ventricular ejection fraction>25%. Exclusion
criteria included patients with ineligible Y-composite graft revasculariza-
tion, unavailable right ITA or SV, chronic renal failure requiring renal
replacement therapy that might prohibit early and 1-year coronary angio-
graphic evaluation, a history of previous cardiac operation, and a medical
history such as malignant disease that might limit the possibility of mid-
term follow-up. Patients with an estimated left ventricular ejection fraction
25% were also excluded because of the possibility of on-pump conver-
sion during OPCAB and the possibility of a need for additional conduit
in a dilated left ventricle.
Of 511 patients who underwent isolated CABG at our institution be-
tween September 2008 and October 2011, patients who were scheduled
to undergo OPCAB (n ¼ 496) were assessed for eligibility. Eligible pa-
tients who were expected to receive an in situ left ITA-based Y-com-
posite graft for complete revascularization (n ¼ 224) based on the
side-arm conduit used for construction of a Y-composite graft were as-
signed randomly to 1 of the 2 operative strategies in a 1:1 manner: The
SV Y-composite graft (the SVG group, n ¼ 112) or the free right ITA
Y-composite graft (the RITA group, n ¼ 112; Figure 1). After the peri-
cardium was opened and the coronary arterial anatomies were assessed
for availability for revascularization using a Y-composite graft, ran-
domization was performed with a web-based block randomization
method with randomly determined block sizes of 4 and 6. After intra-
operative randomization, operative strategies were changed in 5 pa-
tients: on-pump CABG conversion was performed in 1 patient
because of hemodynamic instability, and grafting strategies were
changed in 4 patients because of unsuitable condition of the conduits
or coronary arteries (damaged ITA during harvesting in 2 patients,
small size and poor quality of the SV in 1 patient, and constrictive peri-
carditis with invisible target coronary arteries in 1 patient). Mean age at1028 The Journal of Thoracic and Cardiovascular Surthe time of operation was 62.7  7.8 years. There were no statistically
significant differences in demographic data and preoperative risk fac-
tors between the 2 groups (Table 1).
Operative Strategies
Basic surgical procedures and principles of OPCAB and harvesting
technique of the SV have been described previously.7,10,16 Our surgical
strategies during the study period were performing off-pump revasculariza-
tion using a composite graft based on the left ITA and avoiding aortic ma-
nipulation in most patients. Both the left and right ITAs were harvested
using a skeletonization technique. The proximal dissection of the ITA
was carried to the inferior border of the subclavian vein and the ITA was
divided distally just proximal to the bifurcation. The greater SV from
a lower leg was chosen for use in grafting as opposed to the upper leg
SV to decrease the possibility of size mismatch with native coronary ar-
teries or ITA. SV harvest was initiated after systemic heparinization during
harvest of the left ITA and was performed using an atraumatic, open tech-
nique. Proximal dissection of the SV was carried to approximately 3 cm
below the knee and the SV was divided distally approximately 5 cm prox-
imal to the ankle. Tension on the SV was minimized during harvest, and
manual intraluminal dilatation was avoided.
Immediately after the side-arm conduit (SVor right ITA) was harvested,
it was anastomosed to the side of the left ITA without any pharmacologic
treatment to construct a Y-composite graft. We always performed the Y
anastomosis first, before constructing distal anastomoses, because it was
possible to perfuse ischemicmyocardium after each distal anastomosis dur-
ing OPCAB. After the Y-composite graft was constructed, in almost all the
patients the left anterior descending coronary artery territory was revascu-
larized first by using the left ITAwhile the distal end of the side-arm con-
duit was clamped with an atraumatic bulldog clamp and left to be dilated
spontaneously by the native flow and pressure of the left ITA. The left cir-
cumflex coronary artery territory was then revascularized, followed by the
right coronary artery territory.
A sequential anastomotic technique using each side arm of the Y-com-
posite graft was almost always used for complete revascularization when
more than 2 coronary arterial anastomoseswere needed.When constructing
a sequential anastomosis, longitudinal, perpendicular, or oblique sequential
side-to-side anastomosis was performed to permit efficient use of conduit.
When the length of one or both arms of the Y graft was not sufficient to
reach the target vessels, an additional SV segment from the other lower leg
was harvested to lengthen the graft arm in an I-shape. Patients were given
an initial dose of heparin (1.5 mg/kg) and periodic supplemental doses to
maintain an activated clotting time of>300 seconds. All patients took as-
pirin until the day of surgery and resumed it as soon as possible after sur-
gery, usually 1 day postoperatively. If the patient had a high blood level of
low-density lipoprotein cholesterol (>100 mg/dL) postoperatively, drug
therapy was initiated.Angiographic Evaluation of Graft Patency
Early postoperative (1.4  1.1 days) angiography for evaluation of the
anastomotic sites and patency of the grafts was performed in all the study
patients except the 1 operative death. Informed written consent, including
the possible benefits and risks of postoperative angiography, was obtained
from all patients. One physician initially reviewed all coronary angio-
grams, and consensus was reached after review. Graft patency was graded
in the manner described by FitzGibbon, Burton, and Leach17 (grade A, ex-
cellent; grade B, fair). Grades A and B were treated as patent. Grade O
anastomosis, which included stenosis of 75% or more of vessel diameter
or a totally occluded graft, was treated as occluded.
Evaluation of Early Clinical Outcomes
Operative mortality was defined as any death within 30 days, including
deaths after hospital discharge. The patients were monitored continuouslygery c November 2012
FIGURE 1. Summary flow diagram of participants. ITA, Internal thoracic artery; SV, saphenous vein; LVEF, left ventricular ejection fraction; SVG, saphe-
nous vein Y-composite graft; RITA, right internal thoracic artery Y-composite graft.
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Dwith postoperative electrocardiography during stays in the intensive care
unit and in the general ward until chest tube removal. A standard 12-lead
electrocardiogram was checked daily thereafter during the hospital stay.
Occurrence of any short runs of atrial fibrillation during the hospital stayTABLE 1. Preoperative characteristics and risk factors of the study patien
Variables Total (n ¼ 224) SVG
Age, y 63.0  7.9
Female, n (%) 51 (22.8)
Risk factors, n (%)
Smoking 110 (49.1)
Hypertension 156 (69.6)
Diabetes mellitus 98 (43.8)
Dyslipidemia 33 (14.7)
Overweight (BMI  25 kg/m2) 102 (45.5)
History of stroke 31 (13.8)
Unstable angina 167 (74.6)
Left main disease 84 (37.5)
Three-vessel disease 177 (79.0)
Logistic EuroSCORE,% 3.2  2.5
LVEF,% 57.1  9.6
SVG, Saphenous vein Y-composite graft; RITA, right internal thoracic artery Y-composite
The Journal of Thoracic and Carwas considered to represent development of atrial fibrillation. Respiratory
complications included postoperative pneumonia or>48 hours of pro-
longed ventilator support. Perioperative myocardial infarction was defined
as positive results on at least 2 of 3 different tests—elevated peak serumts
group (n ¼ 112) RITA group (n ¼ 112) P value
63.3  7.8 62.8  8.0 .647
30 (26.8) 21 (18.8) .152
57 (50.9) 53 (47.3) .593
80 (71.4) 76 (67.9) .561
47 (42.0) 51 (45.5) .590
19 (17.0) 14 (12.5) .346
51 (45.5) 51 (45.5) >.999
13 (11.6) 18 (16.1) .333
83 (74.1) 84 (75.0) .878
41 (36.6) 43 (38.4) .783
90 (80.4) 87 (77.7) .623
3.2  2.5 3.3  2.7 .710
58.0  9.7 56.2  9.2 .172
graft; BMI, body mass index; LVEF, left ventricular ejection fraction.
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TABLE 2. Comparison of the number of distal anastomoses between












Per patient 3.56  0.81 3.54  0.86 3.57  0.76 .769
Per the left ITA 1.22  0.47 1.24  0.45 1.20  0.49 .585
Per the second
conduit
2.10  0.75 2.28  0.79 1.91  0.67 <.001
SVG, Saphenous vein Y-composite graft; RITA, right internal thoracic artery Y-com-
posite graft; ITA, internal thoracic artery.
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Dcreatine kinase isoenzyme level (>100 ng/mL), appearance of new Q
waves on the electrocardiogram, or newly developed regional wall motion
abnormalities on the postoperative echocardiogram. Postoperative acute
renal failure was defined as an increase of>50% in serum creatinine level
from the preoperative value or a need for renal replacement therapy regard-
less of serum creatinine level. Low cardiac output syndrome was defined
as a cardiac index<2.0 L/min per square meter or a systolic arterial pres-
sure<90 mm Hg requiring inotropic support (dopamine or dobutamine) of
>5 mg/kg per minute.
End Points
The primary end point of the SAVE RITA trial was the 1-year angio-
graphic patency rate of the distal anastomoses performed with a side-arm
composite graft (SVor right ITA). Secondary end points were early postop-
erative angiographic patency rates and mid-term clinical outcomes, includ-
ing overall survival, freedom from cardiac death, and freedom from major
adverse cardiac and cerebrovascular events (defined as cardiac death
including sudden death during follow-up, acute myocardial infarction,
reintervention including redo-CABG, and cerebrovascular accident).
Statistical Analysis
The study was designed to have 80% power to detect 1-year patency
rates of 93% in the SV versus 95% in the right ITA grafts, with a 1-sided
type I error of 5% and a noninferiority margin of8%. A total of 194 anas-
tomoses were required in each group. Using an estimated average number
of 2 distal anastomoses per conduit, 97 patients were needed to complete
the study cohort. Allowing for a 3% dropout during the perioperative
period and 10% dropout during the 1-year follow-up, we determined
that recruitment of 112 patients in each group was necessary.
Statistical analysis was performedwith the SPSS software package (ver-
sion 12.0; SPSS Inc, Chicago, Ill). Data were expressed as mean standard
deviation, or proportions. Comparisons between the 2 groups were made
using the c2 test and Fisher exact test for categorical variables and the Stu-
dent t-test for continuous variables. A P value of<.05 was considered as
statistically significant. All preoperative and postoperative variables were
compared with an intention-to-treat base. However, numbers of distal anas-
tomoses and patency rates were compared after excluding 5 patients in











Total 3.56  0.81 3.54  0.86 3.57  0.76 .769
LAD territory 1.65  0.56 1.66  0.58 1.62  0.56 .605
LCX territory 1.15  0.49 1.14  0.50 1.17  0.48 .664
RCA territory 0.76  0.57 0.75  0.60 0.78  0.52 .649
SVG, Saphenous vein Y-composite graft; RITA, right internal thoracic artery Y-com-
posite graft; LAD, left anterior descending coronary artery; LCX, left circumflex cor-
onary artery; RCA, right coronary artery.RESULTS
Operative Data
The average length of the harvested skeletonized right
ITA was 14.9  1.5 cm (range, 11-19 cm) and was shorter
than the average length of the greater SV harvested from
a lower leg (16.9  2.1 cm; range, 12-21 cm; P< .001).
The average number of distal anastomoses per patient
(SVG vs RITA groups; 3.54  0.86 vs 3.57  0.76,
P¼ .769) and the average number of distal anastomoses us-
ing the left ITA (SVG vs RITA groups; 1.24  0.45 vs 1.20
 0.49, P¼ .585) were similar between the 2 groups. How-
ever, the number of distal anastomoses using the side-arm
composite graft (SV or right ITA) was larger in the SVG
group than in the RITA group (SVG vs RITA groups; 2.28
 0.79 vs 1.91  0.67, P<.001; Table 2).
When the length of 1 or both arms of the Y graft was not
sufficient for complete revascularization, an additional SV
segment from a lower leg (a third conduit) was harvested
to lengthen the conduit in an I-shape. A third SV conduit
was needed in 46 patients (SVG vs RITA groups; 4 vs 42,1030 The Journal of Thoracic and Cardiovascular SurP< .001). In the SVG group, an additional SV segment
was harvested from the other lower leg to lengthen the SV
composite graft (n ¼ 4; average length, 3.8  0.5 cm). In
the RITA group, the SV was harvested as a third conduit
in 42 patients (average length, 5.8 2.8 cm) and connected
to the left (n ¼ 2) or right (n ¼ 40) ITA to reach the target
vessels. Of 87 patients in the RITA group who had 3-vessel
disease, 40 patients (46.0%) needed an additional SV seg-
ment for complete revascularization of all coronary artery
territories. A sequential anastomotic technique was used
in 204 patients (91%) without intergroup difference (SVG
vs RITA groups; 101 patients vs 103 patients, P ¼ .639).
The number of distal anastomoses in the 3 coronary artery
territories was also similar between the 2 groups (Table 3).Early Clinical Outcomes
In-hospital mortality was 0% in the SVG group and
0.9% (1 of 112 patients) in the RITA group (P>.999). Me-
dian duration of mechanical ventilation and intensive care
unit stay were 16 hours (range, 5-168 hours) and 22 hours
(range, 12-284 hours), respectively. There were no differ-
ences in ventilation and intensive care unit stay times be-
tween the 2 groups (P ¼ .773 and P ¼ .308, respectively).
Postoperative complications included atrial fibrillation
(n ¼ 33, 14.7%), respiratory complications (n ¼ 7,
3.1%), acute renal failure (n ¼ 4, 1.8%), reoperation for
bleeding (n¼ 3, 1.3%), perioperativemyocardial infarction
(n¼ 1, 0.4%), and mediastinitis (n¼ 1, 0.4%). None of the
patients experienced cerebrovascular accident. No statisti-
cally significant differences in early clinical outcomesgery c November 2012
TABLE 4. Comparison of early clinical results
Variables Total (n ¼ 224) SVG group (n ¼ 112) RITA group (n ¼ 112) P value
In-hospital mortality, n (%) 1 (0.4) 0 (0) 1 (0.9) >.999
Postoperative morbidity, n (%)
Atrial fibrillation 33 (14.7) 12 (10.7) 21 (18.8) .090
Respiratory complication 7 (3.1) 4 (3.6) 3 (2.7) >.999
Acute renal failure 4 (1.8) 1 (0.9) 3 (2.7) .622
Reoperation for bleeding 3 (1.3) 2 (1.8) 1 (0.9) >.999
Perioperative MI 1 (0.4) 1 (0.9) 0 (0) >.999
Mediastinitis 1 (0.4) 1 (0.9) 0 (0) >.999
Low cardiac output syndrome 1 (0.4) 0 (0) 1 (0.9) >.999
SVG, Saphenous vein Y-composite graft; RITA, right internal thoracic artery Y-composite graft; MI, myocardial infarction.
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group, 2 patients experienced delayed healing of the lower
leg wound. The hospital stay durations were 7.9  3.1 days
in the SVG group and 7.2  2.9 days in the RITA group
(P ¼ .076).
Early Angiographic Results
Early postoperative angiography demonstrated overall
patency rates of 99.0% (383 of 387 anastomoses) and
99.7% (388 of 389) in the SVG and RITA groups, respec-
tively (P ¼ .216). Patency rate for distal anastomoses using
the left ITAwas 100% (266 of 266). The patency rate of the
SV side-arm composite graft in the SV group was 98.8%
(245 of 248), and was not significantly different from the
patency rate of the right ITA composite graft in the RITA
group (99.5%, 207 of 208; P ¼ .629; Table 5). When the
side-arm composite graft patency rates were compared
based on the target coronary artery territories, SV graft pa-
tency rates were similar to those of the right ITA (Table 6).
During the study period, we did not find any composite graft
with stenosis 50% at the Y-anastomosis site.
DISCUSSION
The current study revealed 2 main findings. First, early
angiographic patency rates and clinical outcomes of
OPCAB using the SVas a side-armY-composite graft based
on the in situ left ITAwere similar to those of OPCAB using
a right ITA composite graft. Second, a third conduit was
needed to extend the right ITA composite graft and reach
the target vessels in 36.4% (40 of 110 patients) of the
RITA group patients.
The SAVE RITA trial was designed to evaluate the SV
compared with the right ITA as a side-arm Y-compositeTABLE 5. Early angiographic patency rates for distal anastomoses
Variables Total (n ¼ 218) SVG g
Overall grafts 771/776 (99.4%) 383/
Grafts using left ITA 266/266 (100%) 135/
Grafts using second conduit 452/456 (99.1%) 245/
Grafts using third conduit 53/54 (98.1%)
SVG, Saphenous vein Y-composite graft; RITA, right internal thoracic artery Y-composite
The Journal of Thoracic and Cargraft in terms of early and 1-year angiographic patency rates
andmid-term clinical outcomes. The study design had a 3%
expected dropout rate, and 5 of 224 randomized patients
(2.2%; SVG vs RITA groups, 3 patients vs 2 patients) did
not undergo their planned operation because of intraopera-
tive events and were excluded during the perioperative
period. Preoperative characteristics and risk factors includ-
ing logistic EuroSCORE were well matched between the 2
groups. All the study patients except 1 operative death (109
patients in each group) underwent early postoperative (7
days) angiography.
Poor long-term patency rates and clinical outcomes have
been reported after CABG performed using SV grafts com-
pared with those after CABG performed with arterial grafts
such as the ITAs and right gastroepiploic artery.2-4 The right
ITA has been considered a second graft of choice because
of its freedom from atherosclerotic changes, excellent
long-term patency, and improved long-term survival
rates.5,6 Merits of right ITA composite grafts have also
been well demonstrated in terms of angiographic patency
and clinical results.7-9,18 SV graft patency is influenced by
3 processes: Thrombosis, fibrointimal hyperplasia, and
atherosclerosis.19 Various efforts to preserve structure and
function of the venous endothelium, including technical
modifications of SV harvesting, pharmacologic treatment,
and genetic engineering, have been made to overcome lim-
itations of SV grafts.20-22 In addition, the SV must tolerate
the pressure and circulatory stress of ascending aortic
pressure and flow when it is used as an aortocoronary
bypass graft.11,12 However, few studies have reported
results of CABG using the SV as a composite graft.10,13,14
Theoretical advantages of using the SV as a side-arm com-
posite graft over an aortocoronary bypass graft are (1) theroup (n ¼ 109) RITA group (n ¼ 109) P value
387 (99.0%) 388/389 (99.7%) .216
135 (100%) 131/131 (100%) —
248 (98.8%) 207/208 (99.5%) .629
3/4 (75.0%) 50/50 (100%) .074
graft; ITA, internal thoracic artery.
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TABLE 6. Comparison of patency rates for distal anastomoses
performed with second conduits between the saphenous veins and







Total 245/248 (98.8%) 207/208 (99.5%) .629
LAD territory 47/47 (100%) 42/43 (97.7%) .478
LCX territory 123/124 (99.2%) 121/121 (100%) >.999
RCA territory 75/77 (97.4%) 44/44 (100%) .533
SVG, Saphenous vein Y-composite graft; RITA, right internal thoracic artery
Y-composite graft; LAD, left anterior descending coronary artery; LCX, left circum-
flex coronary artery; RCA, right coronary artery.
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posed to less pressure and circulatory stress than a conduit
anastomosed to the ascending aorta and (2) the SV compos-
ite graft is exposed continuously to nitric oxide produced
from the left ITA, which may reduce the risk of atheroscle-
rotic disease.11,12 In a previous study performed by our
group,16 adoption of a minimal manipulation technique
for SV harvest and using the SV as a composite graft were
demonstrated to be beneficial in preserving venous endothe-
lial structure and function.
Previous studies reported that early (1 day to 2 months)
patency rates of the SV grafts harvested with a conventional
method and used as a aortocoronary bypass were also lower
than patency rates of arterial grafts, with patency rates rang-
ing from 85.2% to 93.5%.4,23,24 In the current study, we
analyzed early angiographic patency rates and clinical
outcomes of OPCAB using SV composite grafts and
compared them with those of OPCAB using right ITA
composite grafts. The intention-to-treat analysis revealed
that early clinical outcomes including in-hospital mortality
and postoperative complications were similar between the 2
groups. Early postoperative angiography demonstrated that
the patency rates of distal anastomoses using SV composite
grafts were comparable with distal anastomoses performed
using right ITA composite grafts. The patency rates of the
target coronary territories also were similar between the 2
groups. Because the SV composite graft patency rate
(98.8%) in the current study was higher than the SVaorto-
coronary bypass graft patency rate (86.4%) in our previous
retrospective study, we expect the SV composite graft pa-
tency rate to be comparable with that of the right ITA com-
posite graft at 1 year.4,25
Although construction of a composite graft allows the
extensive use of bilateral skeletonized ITA grafts to
revascularize both the left and right coronary systems,7,9
the length of the right ITA is still a limitation for
complete revascularization, particularly in patients with
cardiomegaly. In the current study, the average length of
the harvested skeletonized right ITA was 14.9  1.5 cm,
and 46% of patients with 3-vessel disease in the RITA
group needed an additional conduit to perform complete1032 The Journal of Thoracic and Cardiovascular Surrevascularization. This was in agreement with a previous
study demonstrating that two thirds of distal anastomoses
on the right coronary artery territory were performed using
a third graft in patients with 3-vessel diseasewho underwent
CABG using bilateral ITAY-composite grafts.18Study Limitations
There are limitations to the current study that must be
recognized. First, the current study is not a multicenter
‘‘all-comers’’ study, although it is a prospective, random-
ized, controlled trial. Construction of Y-composite grafts
can be a technically demanding procedure, which may limit
the possibility of generalizing our results to a large surgical
population. Patients from our institution may differ from
those treated elsewhere. The study should be performed
as a multicenter-based trial to overcome the institutional
factor. Second, early graft patency rates and clinical out-
comes do not provide sufficient data to reach a conclusion
on the suitability of the SV composite graft. The SAVE
RITA trial has completed patient enrollment and we are
now following up with patients for their 1-year angiogra-
phies and mid-term clinical outcomes. In addition, it will
be necessary to extend our patency study up to several years
after surgery to demonstrate that the advantages of SV com-
posite grafting are sufficient to overcome the previously
published advantages of the right ITA over the SV as an
additional conduit.References
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Dr Brian F. Buxton (Richmond, Victoria, Australia). Thank
you, Mr. Chairman. I would like to commence by thanking Dr
Hwang for sending me the full paper last week.
Fundamentally, this is a very important randomized, controlled
trial and has the potential of being one of the major trials comparing
the saphenous vein with an arterial graft. So far as I am aware, there
has been no other similar trial. The study was performed in the set-
ting of a left internal thoracic Y-graft configuration. The coronary
bypass procedurewas performed off-pump by an experienced group
of coronary artery bypass surgeons in patients with isolated coro-
nary artery disease. The primary end points, as you saw, were graftThe Journal of Thoracic and Carpatency and major clinical events at 1 year. The initial angiographic
assessment was performed in the week after operation. Stenosis
>75% and occlusion were defined as occlusion.
The paper is well written. The relative graft patencies were de-
termined using a noninferiority statistical model with a difference
of8% between the saphenous vein and the right internal thoracic
artery.
Mr. Chairman, before I go any further, I would like to make one
comment. If we are to improve our techniques with randomized,
controlled trials, what we need to do is have both an end point
with functional and anatomic definitions. For example, fractional
flow reserve is a way we can quantify the impact of the collateral
circulation on study grafts, and the results should be incorporated
in the composite end point. Assessing the collateral circulation by
estimating the degree of stenosis alone in the native circulation is
unreliable, particularly in the range between 50% and 90%.
The authors have indicated that the sample size of 106 patients
in each arm factored in the appropriate power calculation and sam-
ple size, and has allowed for patient dropouts. The term ‘‘interim
analysis’’ is better avoided, and I think should be described as the
early analysis. I disagree with the conclusion in the abstract that it
was shown that noninferiority was not established, because this
was not powered for in the early or interim analysis, but only for
the results at 1 year. The authors have correctly withdrawn that
statement from their presentation.
I have 3 questions that I would like to ask separately. First of all,
there are 5 current, randomized, controlled trials looking at the pa-
tency of arterial and saphenous vein grafts. Each of these trials has
a different definition of graft patency, making interpretation and
meta-analysis very difficult. Could the authors clarify the definition?
For example, is a graftwith a stenosis of 80%patent or is it occluded?
Dr Hwang. Thank you for your nice comments. As you indi-
cated, first of all, we omitted the term ‘‘noninferiority’’ in the pre-
sentation slides this afternoon and in the final submitted
manuscript. Our statistician also advised us that the term should
be used after obtaining the primary end point, the 1-year angio-
graphic patency rate and its confidence interval.
Regarding your first question, graft patency was graded in the
manner described by FitzGibbon and his colleagues. Grades A
and B were treated as patent, and grade O, anastomosis, which in-
cluded stenosis of 75% of the vessel diameter or a totally oc-
cluded graft, was treated as occluded. However, we did not find
any graft with stenosis of 75% during the study period.
Dr Buxton. The FitzGibbon classification, A is completely pat-
ent, B is a stenosis>50% and O is an occlusion. So there is a slight
difference, but basically you have a composite end point of occlu-
sion and>75% stenosis, which is acceptable.
The second question I have is, how do the authors arrive at the
noninferiority margin of8% for the saphenous vein versus the
right internal thoracic artery at the 1-year follow-up?
Dr Hwang. You mean the inferiority margin of8%?
Dr Buxton. Yes. The margin is quite high for a trial that you
designated the end point as being 12 months.
Dr Hwang. Inferiority margin is not an exact percentage that
we expect to obtain; it is the lowest margin of confidence interval.
The saphenous vein patency rates in other previous studies, includ-
ing randomized and nonrandomized studies, were those of the sa-
phenous vein, which was used as an aortocoronary bypass afterdiovascular Surgery c Volume 144, Number 5 1033
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those. We harvest the saphenous vein with minimal manipulation,
avoid the intraluminal dilatation, and use it as a Y-composite graft.
We expect a 1-year patency rate of the saphenous vein to be 93%.
We assume that a 93% patency rate with a confidence interval from
87 to 99, which is 6%, is acceptable to demonstrate noninferior-
ity of the saphenous vein, compared with the right internal thoracic
artery with a patency rate of 95%. There were no references to de-
cide inferiority margin.
Dr Buxton. The only point I am making is that some of the
older observational data suggest high failure rates of saphenous
vein grafts whereas the current, randomized, controlled trials
that we have of Hayward, Goldman, and Collins suggest that, in
fact, the current failure rate of saphenous vein grafts in this setting
has improved or is better than historical data. In other words, the
results of saphenous vein grafting in this setting has lower rates
and therefore it is going to make it more difficult for you to achieve
your end point at 12 months.
And the third question is, if this noninferiority has not been
reached or not demonstrated at 1 year, what plans do you have
to extend the trial to perhaps 5 years, if required?
Dr Hwang.We believe that we will get noninferiority results at
1 year. Regardless of the 1-year result of this randomized trial, we
are planning to extend the study duration and we are going to per-
form follow-up angiograms at 5 years after surgery.
Dr Buxton. Thank you very much and I look forward to hearing
the late results.
DrRobert A. Dion (Genk, Belgium). I just want to make a com-
ment about the technique. You insist on the fact that 36% of your
right mammary artery grafts were too short to perform a full revas-
cularization. When I have to go very far on the inferior wall of the
left ventricle with a free right internal mammary artery, I do the Y
anastomosis last, because it allows me to use, optimally and se-
quentially, the right mammary artery and to decide at the end
where I perform the anastomosis on the left mammary artery
and which orientation I choose. During the past 10 years I very
rarely needed to use a third graft, even in dilated ventricles. It is
indeed technically easier to perform the Y anastomosis at first,
but I think you win efficacy in using the length of the right mam-
mary artery if you do it last. Thank you.
Dr Hwang. Thank you, Dr Dion. I remember that you did
have the same comment to my presentation at the Society of
Thoracic Surgeons meeting last year. We always perform the Y
anastomosis before committing distal anastomoses. By perform-
ing the YAnastomosis first, it is possible to perfuse the coronary
arteries after each distal anastomosis during off-pump coronary
revascularization. We frequently observe that hemodynamic in-
stabilities become stable after each anastomosis, especially while
displacing the heart and grafting the lateral or posterior wall ves-
sels. In addition, the average length of the harvested, skeleton-
ized right ITA was approximately 15 cm and it was not always
enough to revascularize the lateral and posterior–inferior coro-
nary arteries completely in the dilated ventricle.
Dr Guo-Wei He (Tianjin, China). This is a very nice study, par-
ticularly because it is a randomized study. My question, actually, is
very similar to Professor Brian Buxton’s third question. You have
to look at the long-term results for re-angiogram. You never an-
swered that. I would like to make a comment on that.1034 The Journal of Thoracic and Cardiovascular SurThe early occlusion of the graft is largely a result of technical
problems, but the long-term patency and the occlusion rate for
the long term largely depends on the biological characteristics of
the graft.
Now, 10, 15 years ago we did a series of studies looking at the
endothelial function of our grafts, including arterial and saphenous
vein grafts, and we have found that the endothelium of the arterial
graft, including the internal mammary artery and the radial artery
and the gastroepiploic artery, all these arterial grafts release more
nitric oxide as well as endothelium-derived hyperpolarizing factor
than the saphenous veins. That will play a major role in the long
term, beyond 5 or 10 years, as far as the occlusion rates or patency
rates are concerned.
So my comment is you really cannot make a conclusion for the
early 1-year angiogram to say the right mammary or left mammary
artery patency rates are the same as the saphenous vein. So my
comment is really we have to look at the long-term patency.
Dr Hwang. Thank you for your comment. I totally agree with
you.
Dr David Glineur (Brussels, Belgium). Last year we pub-
lished in the Journal of Thoracic and Cardiovascular Surgery
a study on fractional flow reserve measurements with this config-
uration. We concluded that this configuration works perfectly, but
we also found that if you graft a not very stenosed left anterior de-
scending coronary artery, you could have a steal phenomenon in
the vein group. Have you seen this phenomenon at the angio con-
trol at 1 day? Do you think it could be a problem for such
a configuration?
Dr Hwang. Thank you for your question. We did not observe
any flow steal phenomenon on early postoperative angiograms. In-
stead, we observed a few patients who showed bidirectional com-
petition (early washout of grafted coronary artery on graft
angiogram and retrograde filling of graft on native coronary angio-
gram) of distal left ITA grafted for moderately stenosed coronary
arteries. We have to follow up with those patients to look at the fate
of the Y-composite graft.
Dr Zhandong Zhou (Syracuse, NY). I have got a quick ques-
tion. I am just wondering if you see any difference between
a vein graft connected to the left ITA versus a vein graft that con-
nects to the aorta? And second, this was definitely not a blind
study, so do people take a better vein graft for the part that connects
to the mammary artery instead of compared with the vein graft
connected to the aorta?
Dr Hwang. The theoretical advantages of using the saphenous
vein as a composite graft based on the internal thoracic artery
are, first, the saphenous vein is not exposed to direct pressure and
circulatory stress from the ascending aorta and, second, the saphe-
nous vein is exposed continuously to nitric oxide produced from the
in situ left ITA, which may reduce the risk of atherosclerotic
disease.
Dr Zhou.My question is do you see any difference in terms of
patency rate compared with a vein graft connected to the left ITA
versus a vein graft to the aorta? Is there any difference in 1 year?
Dr Hwang. You mean patency rate?
Dr Zhou. Yes.
Dr Hwang. In our previous study, the 1-year patency rate of sa-
phenous vein used in an aortocoronary fashion was<80%. In con-
trast, we recently published in the Annals of Thoracic Surgery thatgery c November 2012
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1 year.
Dr Zhou. Is that the same group of patients or a different group
of patients? So they are not comparable, right?
DrHwang.No, they are not comparable. It is a limitation of ret-
rospective studies.
Dr Zhou. It is in the same group?
Dr Hwang.No, they are not the same groups. We have changed
our strategy in 2006; most aortocoronary saphenous bypasses were
performed before 2006, and most saphenous vein composite grafts
were constructed since 2006.The Journal of Thoracic and CarDr Zhou. But do you see any difference between the second
graft and the third graft in your same group, because the third graft
was a vein graft, right?
Dr Hwang. I am afraid that you misunderstand our third
vein graft being anastomosed to the aorta. The third graft
was connected to the left ITA or to the second graft as an I
shape instead of to the aorta. In our previous retrospective
study, we compared the patency rate of the second arterial
composite and third vein composite grafts. There were no
differences in patency rates between the second and third com-
posite grafts.diovascular Surgery c Volume 144, Number 5 1035
